Parameter
| Biomarker | CD20 | Full name | Cluster of differentiation 20 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Treatment targets, diagnostics |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Biopsy specimens at the time of diagnosis and recurrence (immunohistochemistry, flow cytometry) | ||
| Pathobiological Mechanisms | After treatment with anti-CD20 drugs (e.g., rituximab), some patients exhibit CD20 expression loss upon relapse, which may be associated with tumor cell phenotypic transformation. | ||||
| Clinical Availability Status | Validation phase: Relevant studies have explored its association with prognosis, requiring larger-scale data validation. | ||||
| Notes and Dynamics | It is a potential key variable for the prognostic evaluation of pediatric ALCL, and its expression status can assist in optimizing treatment strategies and stratifying recurrence risk. | ||||